Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
Conditions: Breast Cancer; Breast Neoplasms; Triple Negative Breast Cancer; HER2-positive Breast Cancer Intervention: Drug: Parsaclisib Sponsors: UNC Lineberger Comprehensive Cancer Center; Incyte Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials